drugset / Trial / NCT01198795

Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder

NCT01198795

Phase 4 Completed 162 enrolled Forest Laboratories
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the long-term safety and tolerability of escitalopram (Lexapro) in children 7 to 11 years of age with major depressive disorder (MDD).

Timeline

Start
2010-09
Primary completion
2013-01
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Escitalopram Small molecule 10 mg Oral
Subject Escitalopram Small molecule 20 mg Oral